Lilly - About the company
Lilly is a public company based in Indianapolis (United States), founded in 1876 by Eli Lilly. It operates as a Developer of traditional pharmaceutical medicines. Lilly has raised an undisclosed amount in funding. The company has 1297 active competitors, including 76 funded and 161 that have exited. Its top competitors include companies like AbbVie, Amgen and Gilead.
Company Details
Developer of traditional pharmaceutical medicines. It produces medicines in oncology, cardiovascular, diabetes, critical care, neuroscience, men’s health, and musculoskeletal fields. In 2022, the company recorded annual revenues of $28.54B and a net profit of $6.24B.
- Website
- lilly.com
- Social
- Email ID
- *****@lilly.com
- Phone Number
- +1 **********
- Registered Address
- 2, Bugattivej, Vejle, 7100
Key Metrics
Founded Year
1876
Location
Indianapolis, United States
Stage
Public
Latest Funding Round
Investors
Ranked
4th among 1297 active competitors
Annual Revenue
$65.2B as on Dec 31, 2025
Employee Count
56,138 as on Apr 30, 2026
Exit Details
Public
Legal entities associated with Lilly
Lilly is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ELI LILLY SERVICES INDIA PRIVATE LIMITED CIN: U72200KA2015FTC082300 , India, Active | Aug 17, 2015 | $191M (As on Mar 31, 2025) | 2872 (As on Jan 31, 2024) | |
LILLY HQ ApS CIN: 41281782 , Denmark, Active | Apr 02, 2020 | - | - | |
LILLY A/S CIN: 29606668 , Denmark, Active | May 29, 2006 | - | - | |
LILLY ELI & CO CIN: 59478 , United States, Active | $65.2B (As on Dec 31, 2025) | 39000 (As on Dec 31, 2022) | - |
Lilly's IPO details
Lilly got listed on Jan 06, 1978.
Click here to take a look at Lilly's IPO in detail
Sign up to download Lilly's company profile
Lilly's funding and investors
Lilly has raised funding over 9 rounds. Its first funding round was on Jun 28, 2007. Its latest funding round was a Post IPO round on 2020 for $*****. 1 investor participated in its latest round. Lilly has 13 institutional investors.
Here is the list of recent funding rounds of Lilly:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
2020 | 2888 | Post IPO | 3221 | 3088 | 5308 | 1932 |
Mar 03, 2019 | 6577819 | Conventional Debt | 3431140 | 4365551 | 6578817 | 4399357 |
Aug 01, 2018 | 7460903 | Grant (prize money) | 8397927 | 6232866 | 1525112 |
Access funding benchmarks and valuations. Sign up today!View details of Lilly's funding rounds and investors
Lilly's founders and board of directors
Founder? Claim ProfileThe founders of Lilly is Eli Lilly.
Here are the details of Lilly's key team members:
- Eli Lilly: Founder of Lilly. They are also an angel investor in 15 startups.
View details of Lilly's Founder profiles and Board Members
Lilly's employee count trend
Lilly has 56,138 employees as of Apr 26. Here is Lilly's employee count trend over the years:
Uncover Lilly's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Lilly's Competitors and alternates
Top competitors of Lilly include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of Lilly, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 81/100 | |
2nd | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 81/100 | |
3rd | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 80/100 | |
4th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 79/100 | |
5th |  Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 76/100 | |
6th | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
7th |  AstraZeneca 1999, Cambridge (United Kingdom), Public | Developer of pharmaceutical medicines for oncology and various chronic diseases | - | 73/100 | |
8th |  Pfizer 1849, New York City (United States), Public | Provider of pharmaceutical products for multiple disease treatments | - | 72/100 | |
9th |  Roivant Sciences 2014, New York City (United States), Public | Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 72/100 | |
10th |  Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | 71/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Lilly's competitors? Click here to see the top ones
Lilly's Investments and acquisitions
Lilly has made 129 investments in companies including Crossbow and TRexBio. Lilly has also acquired 35 companies including Ajax and Kelonia.Here is the list of investments & acquisitions:Filter this list
Filter this listDate of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Apr 27, 2026 | Acquisition | 2019 | Cambridge (United States) | |
Apr 20, 2026 | Acquisition | 2021 | Boston (United States) | |
Apr 14, 2026 | Acquisition | 2023 | Houston (United States) |
Want to know more about where corporates are investing? Sign up today!See all investments and acquisitions by Lilly
News related to Lilly
Filter this listMedia has covered Lilly for a total of 730 events in the last 1 year, 480 of them have been about company updates and 49 about partnerships.
•
Lilly's VERVE-102 Shows Significant and Durable LDL-C Reduction in Phase 1b TrialPR Newswire•May 25, 2026•Lilly
•
•
•
Eli Lilly's retatrutide drug shows over 28% weight loss in key obesity trialpharmaphorum•May 21, 2026•Lilly
•
Eli Lilly's Petition Denied by U.S. Supreme Court, Finalizing $220M+ False Claims Act JudgmentPR Newswire•May 19, 2026•Lilly
•
•
Eli Lilly and Company $LLY Shares Acquired by Sapient Capital LLCMarketBeat•May 18, 2026•Lilly, Sapient Capital, Engage Bio
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Lilly
Explore our recently published companies
